New medical therapies for heart failure
Thomas G von Lueder1, Henry Krum2
1Department of Cardiology, Oslo University Hospital Ullevål, 0407 Oslo, Norway.
Insights
Heart failure (HF) is a growing epidemic. While neurohormonal blockers improve outcomes for some, new therapies are needed for acute decompensated HF and HF with preserved ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
- Translational Medicine
Background:
- Heart failure (HF) represents a significant global health challenge in the 21st century.
- Current treatments like diuretics and digoxin have limited impact on long-term outcomes.
- Neurohormonal blockers have improved outcomes in chronic HF with reduced ejection fraction (HFrEF).
Purpose of the Study:
- To review the current understanding of heart failure pathophysiology and treatment limitations.
- To highlight the unmet needs in managing acute decompensated HF and HF with preserved ejection fraction (HFpEF).
- To explore emerging novel pharmacotherapies for diverse HF phenotypes.
Main Methods:
- Literature review of historical and current HF pharmacotherapy.
- Analysis of clinical trial data and pathophysiological insights.
- Survey of novel therapeutic agents in development for HF.
Main Results:
- Significant advances in HF management have been achieved with neurohormonal blockers for HFrEF.
- Knowledge gaps persist regarding the mechanisms and treatment of acute decompensated HF and HFpEF.
- No single drug has substantially reduced long-term event rates for all HF phenotypes.
Conclusions:
- Despite progress, HF remains a complex epidemic with unmet therapeutic needs, particularly for HFpEF and acute decompensation.
- Novel therapeutic strategies targeting diverse pathophysiological pathways are under investigation.
- Future pharmacotherapy holds promise for improving HF management and patient outcomes.
Abstract:
Heart failure (HF) can rightfully be called the epidemic of the 21(st) century. Historically, the only available medical treatment options for HF have been diuretics and digoxin, but the capacity of these agents to alter outcomes has been brought into question by the scrutiny of modern clinical trials. In the past 4 decades, neurohormonal blockers have been introduced into clinical practice, leading to marked reductions in morbidity and mortality in chronic HF with reduced left ventricular ejection fraction (LVEF). Despite these major advances in pharmacotherapy, our understanding of the underlying disease mechanisms of HF from epidemiological, clinical, pathophysiological, molecular, and genetic standpoints remains incomplete. This knowledge gap is particularly evident with respect to acute decompensated HF and HF with normal (preserved) LVEF. For these clinical phenotypes, no drug has been shown to reduce long-term clinical event rates substantially. Ongoing developments in the pharmacotherapy of HF are likely to challenge our current best-practice algorithms. Novel agents for HF therapy include dual-acting neurohormonal modulators, contractility-enhancing agents, vasoactive and anti-inflammatory peptides, and myocardial protectants. These novel compounds have the potential to enhance our armamentarium of HF therapeutics.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Cardiomyopathy V: Interprofessional Care
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure Drugs: β-Blockers